Advertisement

Clinical and Experimental Medicine

, Volume 18, Issue 3, pp 347–353 | Cite as

Granulomatosis with polyangiitis: clinical course and outcome of 60 patients from a single center in South India

  • Vineeta ShobhaEmail author
  • Saba Fathima
  • Ravi Prakash
Original Article

Abstract

Granulomatosis with polyangiitis (GPA) previously known as Wegener’s granulomatosis is one of the forms of idiopathic systemic vasculitis. There is very scanty data available on GPA in Asian and Indian population. We studied data of 60 patients from southern India, diagnosed with GPA to describe the physical characteristics, the treatment, and outcome. Patients who fulfilled any two of the four criteria proposed by the American College of Rheumatology, and those with clinical features of GPA with ANCA positivity and histopathological confirmation, were included in the study. Disease activity and damage were assessed by Birmingham Vasculitis Activity Score v. 3 (BVAS v. 3) and Vasculitis Damage Index (VDI), respectively. Relapses were defined as recurrence of GPA of sufficient severity to require treatment or increase in the dose of treatment on a patient who was previously stable. Out of 60 patients, initial BVAS evaluation showed that 57 (95%) patients had severe disease and 3 (5%) patients had limited disease where median BVAS was 21.5 (range 17–44). Follow-up BVAS evaluation for severe disease showed that 13 (22.8%) patients continued with severe disease of which 9 patients did not survive, 24 (42.3%) had remission, 11 (19.2%) had persistent disease, and 9 (15.7%) were lost to follow-up. The mean VDI score was 2.5 ± 2. Renal involvement was established in 42 (70%) patients. Upper and lower respiratory involvement was seen in 38 (63%) patients. Nervous system involvement was noted in the 15 (25%) patients. Articular manifestations were seen in 16 (27%) patients. Diverse clinical manifestation delay early diagnosis and treatment of this potentially treatable vasculitis. Focused approach could expedite early diagnosis and can reduce the mortality.

Keywords

GPA Granulomatosis with polyangiitis Wegener’s granulomatosis BVAS Vasculitis Damage Index 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

References

  1. 1.
    Finkielman JD, Lee AS, Hummel AM, Viss MA, Jacob GL, Homburger HA, for the WGET Research Group, et al. ANCA are detectable in nearly all patients with active severe Wegener’s granulomatosis. Am J Med. 2007;120(643):e9–14.Google Scholar
  2. 2.
    Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116:488–98.CrossRefPubMedGoogle Scholar
  3. 3.
    Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36–44.CrossRefPubMedGoogle Scholar
  4. 4.
    The Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med. 2005;352:351–61.CrossRefGoogle Scholar
  5. 5.
    Luqmani R, Suppiah R, Edwards CJ, et al. Mortality in Wegener’s granulomatosis: a bimodal pattern. Rheumatology (Oxford). 2011;50(4):697–702 (Epub 2010 Nov 25).CrossRefGoogle Scholar
  6. 6.
    Zycinska K, Wardyn KA, Tyszko P, et al. Analysis of early death based on the prediction model in Wegener’s granulomatosis with pulmonary and renal involvement. J Physiol Pharmacol. 2007;58(8 Suppl 5(Pt 2)):829–37.PubMedGoogle Scholar
  7. 7.
    Yegin EG, Can M, Yilmaz N, Aydin SZ, Yavuz S, Tuglular S, Direskeneli H. Activity and damage in granulomatosis with polyangiitis. Int J Rheum Dis. 2013;16(1):61–71.CrossRefPubMedGoogle Scholar
  8. 8.
    Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum. 1990;33(8):1101–7CrossRefPubMedGoogle Scholar
  9. 9.
    Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994; 87:67 The European Vasculitis Study Group website. http://www.vasculitis.org/images/documents/bvas_v3.0.pdf.
  10. 10.
    Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage COS, Adu D. Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheumatol. 1997;40:371–80.CrossRefGoogle Scholar
  11. 11.
    Bambery P, Sakhuja V, Bhusnurmath SR, Jindal SK, Deodhar SD, Chaugh KS, et al. Wegener’s granulomatosis: clinical experience with eighteen patients. J Assoc Physicians India. 1992;40:597–600.PubMedGoogle Scholar
  12. 12.
    Kumar A, Pandhi A, Menon A, Sharma SK, Pande JN, Malaviya AN. Wegener’s granulomatosis in India: clinical features, treatment and outcome of twenty five patients. Indian J Chest Dis Allied Sci. 2001;43:1–7.Google Scholar
  13. 13.
    Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients over 21 years. Ann Intern Med. 1983;98:76–85.CrossRefPubMedGoogle Scholar
  14. 14.
    Holle JU, Gross WL, Latza U, et al. Improved outcome in 445 patients with Wegener’s granulomatosis in a German vasculitis center over four decades. Arthritis Rheum. 2011;63(1):257–66CrossRefPubMedGoogle Scholar
  15. 15.
    Koldingsnes W, et al. Epidemiology of Wegener’s granulomatosis in northern Norway. Arthritis Rheumatol. 2000;43(11):2481–7.CrossRefGoogle Scholar
  16. 16.
    Martínez-Morillo M, et al. Granulomatosis with Polyangiitis (Wegener). Description of 15 cases. Reumatol Clin. 2012;8:15–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Kim HW, et al. ANCA-associated vasculitis: report from Korea. Clin Exp Nephrol. 2013;17(5):708–11.CrossRefPubMedGoogle Scholar
  18. 18.
    Reinhold-Keller E, et al. An interdisciplinary approach to the care of patients with Wegener’s granulomatosis: long-term outcome in 155 patients. Arthritis Rheumatol. 2000;43(5):1021–32.CrossRefGoogle Scholar
  19. 19.
    Pierrot-Deseilligny Despujol C, et al. Predictors at diagnosis of a first Wegener’s granulomatosis relapse after obtaining complete remission. Rheumatology (Oxford). 2010;49(11):2181–90.CrossRefGoogle Scholar
  20. 20.
    Dunlap NE, Briles DE. Immunology of tuberculosis. Med Clin North Am. 1993;77:1235–51.CrossRefPubMedGoogle Scholar
  21. 21.
    Flores-Suárez LF, Cabiedes J, Villa AR, et al. Prevalence of antineutrophil cytoplasmic autoantibodies in patients with tuberculosis. Rhuematology (Oxford). 2003;42:223–9.CrossRefGoogle Scholar
  22. 22.
    Pradhan VD, Badakere SS, Ghosh K, Pawar AR. Spectrum of anti-neutrophil cytoplasmic antibodies in patients with pulmonary tuberculosis overlaps with that of Wegener’s granulomatosis. Indian J Med Sci. 2004;58:283–8.PubMedGoogle Scholar
  23. 23.
    Davies DJ, Moran JE, Niall JF, Ryan GB. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J (Clin Res Ed). 1982;285(6342):606.CrossRefGoogle Scholar
  24. 24.
    Phillip R, Luqmani R. Mortality in systemic vasculitis: a systematic review. Clin Exp Rheumatol. 2008;26:S94–104.PubMedGoogle Scholar
  25. 25.
    Anderson G, Coles ET, Crane M, Douglas AC, Gibbs AR, Geddes DM. Wegener’s granuloma. A series of 265 British cases seen between 1975 and 1985. A report by a sub-committee of the British Thoracic Society Research Committee. Q J Med. 1992;83:427–38.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Clinical Immunology and RheumatologySt. Johns National Academy of Health SciencesBengaluruIndia
  2. 2.Department of MedicineSt. John’s National Academy of Health SciencesBengaluruIndia
  3. 3.Department of NephrologySt. John’s National Academy of Health SciencesBengaluruIndia

Personalised recommendations